Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
17.66
-1.23 (-6.51%)
At close: Jan 30, 2026, 4:00 PM EST
18.01
+0.35 (1.98%)
After-hours: Jan 30, 2026, 7:10 PM EST
Neurogene Revenue
In the year 2024, Neurogene had annual revenue of $925.00K.
Revenue (ttm)
$925.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
107
Market Cap
273.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 925.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNGNE News
- 19 days ago - Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - Business Wire
- 26 days ago - Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Neurogene: From Speculation To Execution With NGN-401 - Seeking Alpha
- 2 months ago - Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
- 2 months ago - Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome - Business Wire
- 3 months ago - Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome - Business Wire